Neuropace

NPCE · NASDAQ

$13.51+$0.74 (+5.79%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $12.77

Latest news

Press releaseSep 1, 5:01 PM ETBusiness Wire
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
Press releaseAug 31, 4:05 PM ETBusiness Wire
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
Press releaseAug 11, 4:05 PM ETBusiness Wire
NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NewsJul 29, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsJul 29, 8:03 AM ETAvi Kapoor
Avis Budget Posts Weak Q2 Results, Joins Fiverr International, Costar Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Press releaseJul 28, 4:01 PM ETBusiness Wire
NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy
Press releaseMay 29, 8:05 AM ETBusiness Wire
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
Press releaseMay 29, 8:00 AM ETBusiness Wire
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
NewsMay 12, 5:38 PM ET
NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript
Press releaseMay 12, 4:05 PM ETBusiness Wire
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NewsMay 12, 7:11 AM ET
Earnings Scheduled For May 12, 2026
Press releaseApr 29, 4:05 PM ETBusiness Wire
NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026
Press releaseApr 27, 7:30 AM ETBusiness Wire
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
Press releaseApr 10, 4:05 PM ETBusiness Wire
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
NewsMar 23, 8:05 AM ET
12 Health Care Stocks Moving In Monday's Pre-Market Session
Press releaseMar 5, 4:30 PM ETBusiness Wire
NeuroPace to Present at the Leerink Global Healthcare Conference
NewsMar 3, 4:08 PM ET
Earnings Summary: NeuroPace Q4
Press releaseMar 3, 4:05 PM ETBusiness Wire
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
NewsMar 3, 6:11 AM ET
Earnings Scheduled For March 3, 2026
NewsMar 2, 11:01 AM ET
Earnings Outlook For NeuroPace
Press releaseFeb 20, 4:30 PM ETBusiness Wire
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
NewsJan 27, 8:00 AM ET
Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock
Press releaseJan 13, 7:30 AM ETBusiness Wire
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
Press releaseDec 31, 9:00 AM ETBusiness Wire
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
Press releaseDec 17, 8:00 AM ETBusiness Wire
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
Press releaseDec 8, 8:00 AM ETBusiness Wire
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
Press releaseDec 2, 8:01 AM ETBusiness Wire
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
Press releaseNov 24, 8:00 AM ETBusiness Wire
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
NewsNov 5, 12:05 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsNov 5, 7:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Press releaseNov 4, 4:05 PM ETBusiness Wire
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Press releaseOct 22, 8:00 AM ETBusiness Wire
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
Press releaseAug 28, 8:00 AM ETBusiness Wire
NeuroPace to Participate in Upcoming Healthcare Conferences
Press releaseAug 12, 4:05 PM ETGlobe Newswire
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
Press releaseJul 29, 4:05 PM ETGlobe Newswire
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
Press releaseJul 6, 10:00 AM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

NeuroPace to Participate in 2026 Cantor Global Healthcare Conference

NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference

NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Avis Budget Posts Weak Q2 Results, Joins Fiverr International, Costar Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

NeuroPace Receives FDA Guidance on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

NeuroPace Reports Q1 2026 Results: Full Earnings Call Transcript

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Earnings Scheduled For May 12, 2026

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference

12 Health Care Stocks Moving In Monday's Pre-Market Session

NeuroPace to Present at the Leerink Global Healthcare Conference

Earnings Summary: NeuroPace Q4

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

Earnings Scheduled For March 3, 2026

Earnings Outlook For NeuroPace

NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

Beyond The Numbers: 5 Analysts Discuss NeuroPace Stock

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

NeuroPace to Participate in Upcoming Healthcare Conferences

NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE